Dr. Reddy's Laboratories, Inc. launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma

HYDERABAD, India--(BUSINESS WIRE)--Dr Reddy’s Laboratories (NYSE: RDY) today announced the launch of Reditux™, the Dr Reddy’s brand of rituximab, a monoclonal antibody (MAb) used in the treatment of Non-Hodgkin’s Lymphoma. The launch event was held in Hyderabad with over 100 leading oncologists attending the unveiling of the RedituxTM brand followed by a technical session on the development of the drug.